LGD-2226 vs LGD-3303

LGD-2226 wins for:

• Libido and sexual behavior preservation (rat data), making it the only SARM in its class not to tank sexual performance in the classic models
• Favorable bone-anabolic effects with minimal prostate stimulation at standard anabolic doses
• Longer half-life and convenient once-daily oral protocols

LGD-3303 wins for:

• Noticeably drier, harder gains and vascularity — it's the SARM cut add-on or dry bridge specialists look for
• Higher overall anabolic potency and more robust lean mass accrual (among SARMs, second only to ligandrol in real logs)
• Cleaner separation between muscle/prostate action (full AR agonism in muscle, partial in prostate), favoring a safe tissue-selectivity profile
• Slightly better vendor availability and higher batch-to-batch reliability lately

Pick LGD-2226 if:

• The goal is a bone-anabolic effect with minimal androgenic and estrogenic spillover
• Libido preservation is an explicit priority (e.g., stacking with compounds notorious for suppression)
• A SARM is needed for long-term bridging and minimizing cumulative HPTA impact
• Niche research on quinolinone backbone SARMs is of particular interest
• Once-daily oral dosing fits the protocol better than multi-time split routines

Pick LGD-3303 if:

• The research focus is lean tissue gain with hard vascularity and minimum water retention
• This is a recomp, mini-cut, or dry bridge protocol—especially alongside a TRT substrate
• The protocol requires rapid plasma SARM turnover (short half-life) for precise cycle management
• The goal is to avoid "wet" look and bulk-associated bloat seen with other potent SARMs
• More robust user data and dosing logs are valued as a research-quality criterion